Peter Albers, MD, University of Düsseldorf, Düsseldorf, Germany, discusses the challenges of rolling out prostate cancer screening, commenting on the need for strategies which separate indolent prostate cancer from aggressive cancer, and highlights the role of molecular predictors for risk-adapted screening. This interview took place at the virtual European Association of Urology (EAU) Virtual Meeting 2021.
